Emerging Therapies: Phase 3 Efficacy & Safety Data Easing the Disease Burden of Patients with Atopic Dermatitis
-
- Medicine
JAK-STAT inhibitors: oral and topical
JAK-STAT inhibitors vs dupilumab
IL-13 antagonists
IL-31 antagonists
JAK-STAT inhibitors: oral and topical
JAK-STAT inhibitors vs dupilumab
IL-13 antagonists
IL-31 antagonists
16 min